se of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers

niversity Hospital Ghent0 sites20 target enrollmentSeptember 29, 2021

Overview

No summary available.

Registry

who.int

Start Date

September 29, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

niversity Hospital Ghent

•\-Patient is 18 years or older.
•\-Signed Informed Consent.
•\-Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory.
•\-Subject should have a routine clinical 18F\-FDG PET/CT performed within two months prior to the study scan.
•\-Female patients should be either post\-menopausal, surgically sterile, or using effective contraceptive methods (failure rate less than 1% per year when used consistently and correctly: combined hormonal contraception associated with inhibition of ovulation, progestogen\-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone\-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 10
•F.1\.3 Elderly (\>\=65 years) yes

•\-Patient has known other active malignancy.
•\-Patient is potentially pregnant (urinary hCG test can be performed in case of doubt) or breastfeeding.
•\-Patient is mentally or legally incapacitated.